• 1. Ethyl-for-methyl substitution enhances the subtype specificity of mecamylamine analogues
  David Mangan,Neasa McNabola,Emily H. Clark,Isabel Bermudez,Susan Wonnacott,J. Mike Southern Org. Biomol. Chem. 2019 17 9892
• 2. A new synthesis and preliminary evaluation of some analogues of mecamylamine – a compound with anti-addiction properties
  David Mangan,Neasa McNabola,Emily H. Clark,Isabel Bermudez,Susan Wonnacott,J. Mike Southern Org. Biomol. Chem. 2016 14 10787
• 3. Strain-promoted retro-Dieckmann-type condensation on [2.2.2]- and [2.2.1]bicyclic systems: a fragmentation reaction for the preparation of functionalized heterocycles and carbocycles
  Elena Moreno-Clavijo,Antonio J. Moreno-Vargas,Ana T. Carmona,Inmaculada Robina Org. Biomol. Chem. 2013 11 7016
• 4. Beckmann rearrangements in bicyclo[2.2.1]heptan-2-one oximes
  Peter A. Hunt,Christopher J. Moody,Alexandra M. Z. Slawin,David J. Williams,Peter L. Myers,Colin Smith J. Chem. Soc. Perkin Trans. 1 1992 831
• 5. Beckmann rearrangements in bicyclo[2.2.1]heptan-2-one oximes
  Peter A. Hunt,Christopher J. Moody,Alexandra M. Z. Slawin,David J. Williams,Peter L. Myers,Colin Smith J. Chem. Soc. Perkin Trans. 1 1992 831

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Bicyclic monoterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Monoterpenoids Bicyclic monoterpenoids
• Solvents and Organic Chemicals Organic Compounds Alcohol/Ether
• Solvents and Organic Chemicals Organic Compounds Aldehyde/Ketone

Recent Advances in the Study of Norbornan-2-one (497-38-1): Applications and Mechanisms in Chemical Biology and Pharmaceutical Research

Norbornan-2-one (CAS: 497-38-1), a bicyclic ketone with a unique structural framework, has garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug synthesis, material science, and biocatalysis. Recent studies have explored its potential as a key intermediate in the development of novel therapeutics, particularly in the context of enzyme inhibition and chiral synthesis. This research brief synthesizes the latest findings on norbornan-2-one, highlighting its mechanistic roles, synthetic utility, and emerging applications in biomedicine.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of norbornan-2-one derivatives as selective inhibitors of cytochrome P450 enzymes, which are critical targets in drug metabolism and toxicity studies. The research team utilized computational docking and kinetic assays to identify structural modifications that enhance binding affinity while minimizing off-target effects. These findings underscore the compound's potential in designing safer and more effective prodrugs.

In the realm of asymmetric synthesis, norbornan-2-one has emerged as a valuable chiral auxiliary. A breakthrough paper in Angewandte Chemie (2024) detailed its use in the stereoselective construction of complex natural product scaffolds, achieving enantiomeric excesses exceeding 99% through innovative organocatalytic protocols. This advancement addresses longstanding challenges in the synthesis of bioactive molecules with quaternary carbon centers.

Recent investigations into the compound's physicochemical properties have revealed unexpected stability in physiological conditions, as reported in ACS Chemical Biology (2024). Nuclear magnetic resonance (NMR) studies coupled with molecular dynamics simulations showed that norbornan-2-one maintains structural integrity across a wide pH range, making it particularly suitable for drug delivery applications where metabolic stability is paramount.

Emerging applications in materials science have expanded the utility of norbornan-2-one beyond traditional pharmaceutical contexts. A 2024 study in Advanced Functional Materials demonstrated its incorporation into polymer networks as a photo-responsive moiety, enabling the development of smart biomaterials with tunable mechanical properties. This interdisciplinary approach bridges chemical synthesis with biomedical engineering, opening new avenues for implantable devices and controlled release systems.

The safety profile of norbornan-2-one has been systematically evaluated in recent preclinical trials. Toxicology data published in Chemical Research in Toxicology (2023) indicate favorable ADME (absorption, distribution, metabolism, and excretion) characteristics at therapeutic doses, with no observed genotoxicity in standard assays. These findings support its continued development as a pharmaceutical building block.

Future research directions highlighted in recent review articles emphasize the need for structure-activity relationship (SAR) studies to optimize norbornan-2-one derivatives for specific therapeutic targets. Additionally, the integration of continuous flow chemistry approaches may enhance the scalability of norbornan-2-one-based syntheses, addressing current limitations in industrial production.

• 87507-62-8(1,5-Methano-4H-inden-4-one, octahydro-, (1R)-)
• 859990-17-3(Norcamphor, 5,6-dimethyl- (5CI))
• 87451-48-7(1,5-Methano-4H-inden-4-one, octahydro-)
• 87507-38-8(1,5-Methano-4H-inden-4-one, octahydro-, (1S)-)
• 92000-44-7(1H-Indene-1,4(2H)-dione, hexahydro-2,5-dimethyl-)
• 29927-85-3(octahydro-1H-inden-1-one)
• 2826-65-5(1H-Inden-1-one,octahydro-, (3aR,7aR)-rel-)
• 94713-18-5(Cyclohexanone,2-methyl-4-(octahydro-4,7-methano-1H-inden-5-yl)-)
• 27943-47-1(Bicyclo[2.2.1]heptane-2,5-dione)
• 87507-35-5(1,5-Methanopentalen-4(1H)-one, hexahydro-, (1R)-)